Results of a phase Ib trial evaluating the safety and clinical activity of sapanisertib (TAK 228) in combination with serabelisib (TAK 117) and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.
Casey Williams(Creighton University), Luis Rojas‐Espaillat(Avera McKennan Hospital & University Health Center), Kirstin Williams(Avera Health), David Starks(Cleveland Clinic), Brian Leyland‐Jones(Avera Health), Nandini Dey(University of South Dakota), Pradip De(University of South Dakota), Amy Krie(Amgen (United States))
Cited by 9
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|726
Laparoendoscopic single-site surgery (LESS) in gynecology: a multi-institutional evaluation
|American Journal of Obstetrics and Gynecology|2010|136
RET rearrangements are actionable alterations in breast cancer
|Nature Communications|2018|127